|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM276618831 |
| 003 |
DE-627 |
| 005 |
20231225012427.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2017 xx |||||o 00| ||jpn c |
| 024 |
7 |
|
|a 10.14989/ActaUrolJap_63_9_351
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0922.xml
|
| 035 |
|
|
|a (DE-627)NLM276618831
|
| 035 |
|
|
|a (NLM)28992664
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a jpn
|
| 100 |
1 |
|
|a Chikazawa, Ippei
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Clinical Study on the Efficacy and Continuous Docetaxel Based Chemotherapy Treatment for Castration-Resistant Prostate Cancer
|
| 264 |
|
1 |
|c 2017
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 16.03.2018
|
| 500 |
|
|
|a Date Revised 02.12.2018
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a We report a retrospective study on the efficacy, adverse events and the factors for continuous docetaxel (DOC) therapy for patients with castration-resistant prostate cancer (CRPC). Between April 2007 and April 2015, 37 CRPC patients were treated with DOC therapy at Kanazawa Medical University Hospital. DOC was administered every 3 weeks at 70 mg/m2. Prostatic specific antigen (PSA) level, adverse events, cycles of DOC therapy, survival time and clinical passage were examined. Fifteen patients showed a decrease in PSA level of 50% or more, 9 patients showed less than 50% decrease in PSA level and 13 patients showed no decrease in PSA level. Adverse effect of grade 3 consisted of neutropenia in 29.7% and leukocytopenia in 10.8%. The median number of treatment cycles was 11.7 courses. The patients were divided into two groups ; the first group comprised of 26 patients who received short-term DOC therapy (≤10 cycles) and the second group comprised of 11 patients who received long-term DOC therapy (≥11 cycles). The 1-year survival rate was 59 and 100% for the short-term and long-term groups, respectively. Long-term treatment was related to pretreatment PSA nadir, time to progression of CRPC and serum lactate dehydrogenase level
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Castration resistant prostate cancer
|
| 650 |
|
4 |
|a Docetaxel
|
| 650 |
|
7 |
|a Antineoplastic Agents
|2 NLM
|
| 650 |
|
7 |
|a Taxoids
|2 NLM
|
| 650 |
|
7 |
|a Docetaxel
|2 NLM
|
| 650 |
|
7 |
|a 15H5577CQD
|2 NLM
|
| 700 |
1 |
|
|a Inoue, Shinya
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Nakazawa, Yusuke
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Nakai, Dan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Morita, Nobuyo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tanaka, Tatsuro
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Motoo, Yoshiharu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Miyazawa, Katsuhito
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Hinyokika kiyo. Acta urologica Japonica
|d 1962
|g 63(2017), 9 vom: 09. Sept., Seite 351-357
|w (DE-627)NLM012631779
|x 0018-1994
|7 nnns
|
| 773 |
1 |
8 |
|g volume:63
|g year:2017
|g number:9
|g day:09
|g month:09
|g pages:351-357
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.14989/ActaUrolJap_63_9_351
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_2001
|
| 912 |
|
|
|a GBV_ILN_2003
|
| 912 |
|
|
|a GBV_ILN_2005
|
| 912 |
|
|
|a GBV_ILN_2006
|
| 912 |
|
|
|a GBV_ILN_2008
|
| 912 |
|
|
|a GBV_ILN_2010
|
| 912 |
|
|
|a GBV_ILN_2012
|
| 912 |
|
|
|a GBV_ILN_2018
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 63
|j 2017
|e 9
|b 09
|c 09
|h 351-357
|